According to estimates, while the vulnerable population in the country is a whopping 13 crore, the availability of influenza vaccine stands at just one lakh doses.
The governments move is in addition to its plans to invoke compulsory licensing to allow generic versions of Roches Tamiflu from domestic players Cipla and Ranbaxy, and forms part of WHOs influenza preparedness plan to tackle the bird flu pandemic in case it strikes the country.
According to industry sources, the health ministry has held talks with manufacturers with a capacity to produce up to 20 million doses and with capabilities to scale up production. This will be enough to vaccinate those who would be most exposed to the virus in case of an emergency attack.
Hyderabad-based Bharat Biotech, which recently had discussions with the health ministry on this, said it is readying its manufacturing facility in view of the impending threat.
Says Bharat Biotech chairman Dr Krishna M Ella, Apart from funds in the range of Rs 50-60 crore, we would also want the government to enable us to tie up with organisations like ICMR for vaccine research. The government should also go into a mission mode, and help import the virus strains from WHOs London facility.